Literature DB >> 18630839

A study of the reproducibility of a fluorescence in situ hybridization bladder cancer detection assay.

Shannon M Brankley1, Elizabeth J Adams, Michael R Christensen, Cortney R Everts, Jennifer D Lund, Trynda N Oberg, Amy M Plagge, Angela H Zieman, Benjamin R Kipp, Kevin C Halling.   

Abstract

OBJECTIVE: To assess the reproducibility of the UroVysion fluorescence in situ hybridization (FISH) bladder cancer detection assay. STUDY
DESIGN: Thirteen specimens (2 negative, 3 low-level positive [1-10% abnormal cells], 5 mid-level positive [11-75%], and 3 high-level positive [>75%]) were analyzed by 7 cytotechnologists. Each cytotechnologist rendered an overall diagnosis of positive or negative and determined the percentage of abnormal urothelial cells for all positive specimens.
RESULTS: The interobserver reproducibility of the assay was 100% for mid-level and high-level positive specimens, 93% for negative specimens, and 78% for low-level positive specimens. The range of percent abnormal determinations was highest for mid-level positive specimens, with mean SDs of 1.8%, 16.4% and 10.1% for the low-, mid-, and high-level positives, respectively.
CONCLUSION: There was a high level of reproducibility among the mid- and high-level positive specimens. The reproducibility for low-level positive specimens was lowest, suggesting that such specimens should be reviewed by a second technologist to ensure an accurate diagnosis. The findings of this study are important for further elucidating the clinical value of quantitative FISH analysis in the management of patients undergoing FISH testing for bladder cancer.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18630839

Source DB:  PubMed          Journal:  Anal Quant Cytol Histol        ISSN: 0884-6812            Impact factor:   0.302


  3 in total

1.  Outcomes of Patients With Double-Hit Lymphoma Who Achieve First Complete Remission.

Authors:  Daniel J Landsburg; Marissa K Falkiewicz; Joseph Maly; Kristie A Blum; Christina Howlett; Tatyana Feldman; Anthony R Mato; Brian T Hill; Shaoying Li; L Jeffrey Medeiros; Pallawi Torka; Francisco Hernandez-Ilizaliturri; Nishitha M Reddy; Arun Singavi; Timothy S Fenske; Julio C Chavez; Jason B Kaplan; Amir Behdad; Adam M Petrich; Martin A Bast; Julie M Vose; Adam J Olszewski; Cristiana Costa; Frederick Lansigan; James N Gerson; Stefan K Barta; Oscar Calzada; Jonathon B Cohen; Jennifer K Lue; Jennifer E Amengual; Xavier Rivera; Daniel O Persky; David J Peace; Sunita Nathan; Ryan D Cassaday
Journal:  J Clin Oncol       Date:  2017-05-05       Impact factor: 44.544

2.  Quantitative fluorescence in situ hybridization and its ability to predict bladder cancer recurrence and progression to muscle-invasive bladder cancer.

Authors:  Benjamin R Kipp; Mihaela Tanasescu; Terry A Else; Sandra C Bryant; R Jeffrey Karnes; Thomas J Sebo; Kevin C Halling
Journal:  J Mol Diagn       Date:  2009-01-29       Impact factor: 5.568

3.  Fluorescence in situ hybridization in 1 mL of selective urine for the detection of upper tract urothelial carcinoma: a feasibility study.

Authors:  J E Freund; E I M L Liem; C D Savci-Heijink; T M de Reijke
Journal:  Med Oncol       Date:  2018-11-29       Impact factor: 3.064

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.